Indegene Limited announced the appointment of Ms. Jill Mary De Simone as an Additional Director (Non-Executive Independent Director). The decision was approved by the Board of Directors on January 22, 2026, based on the recommendation of the Nomination and Remuneration Committee. Ms. De Simone's appointment is for a term of three years, effective from January 22, 2026, to January 21, 2029, and is subject to shareholder approval. The company affirms that Ms. De Simone is not debarred from holding the office of Director by any SEBI order or other authority. Ms. De Simone is an accomplished biopharmaceutical executive with extensive experience in global healthcare organizations. Her career includes leadership roles at Merck, Teva, and Bristol Myers Squibb, where she managed P&L responsibilities and launched therapies in oncology, HIV, women’s health, and general medicine. She currently advises companies on commercialization and leadership transitions and serves on the boards of life sciences companies. She is not related to any Director of the Company.
